The Efficacy and Cost-Effectiveness of Umeclidinium/Vilanterol versus Tiotropium in Symptomatic Patients with Chronic Obstructive Pulmonary Disease

BACKGROUND: Both long-acting muscarinic antagonists (LAMAs) and long-acting β2-agonists (LABAs) are widely used in the treatment of chronic obstructive pulmonary disease (COPD). A novel LAMA/LABA combination of umeclidinium/vilanterol (UMEC/VI; 62.5 μg/25 μg) is approved for chronic obstructive pulm...

Descripción completa

Detalles Bibliográficos
Autores principales: Gong, Yinhua, Lin, Chen, Jin, Yifeng, Chen, Rong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9436597/
https://www.ncbi.nlm.nih.gov/pubmed/36060827
http://dx.doi.org/10.1155/2022/2878648

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9436597/
https://www.ncbi.nlm.nih.gov/pubmed/36060827
http://dx.doi.org/10.1155/2022/2878648

Ejemplares similares